Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 30 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Matikas A, Möbus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmström P, Schmatloch S, Johansson H, Hellström M, Brandberg Y, Gnant M, Loibl S, Foukakis T, Bergh J, SweBCG, ABCSG and GBG
J Clin Oncol, 42(26):3077-3082, 17 Jul 2024
Cited by: 0 articles | PMID: 39018515 | PMCID: PMC11379357
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic and predictive impact of NOTCH1 in early breast cancer.
Engel J, Wieder V, Bauer M, Kaufhold S, Stückrath K, Wilke J, Hanf V, Uleer C, Lantzsch T, Peschel S, John J, Pöhler M, Weigert E, Bürrig KF, Buchmann J, Santos P, Kantelhardt EJ, Thomssen C, Vetter M
Breast Cancer Res Treat, 17 Aug 2024
Cited by: 0 articles | PMID: 39153127
Add to export list
PIK3CA-mutations in breast cancer.
Reinhardt K, Stückrath K, Hartung C, Kaufhold S, Uleer C, Hanf V, Lantzsch T, Peschel S, John J, Pöhler M, Bauer M, Bürrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M
Breast Cancer Res Treat, 196(3):483-493, 24 Oct 2022
Cited by: 28 articles | PMID: 36279023 | PMCID: PMC9633529
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients.
Schüler K, Bethmann D, Kaufhold S, Hartung C, Stückrath K, Lantzsch T, Uleer C, Hanf V, Peschel S, John J, Pöhler M, Buchmann J, Bürrig KF, Weigert E, Thomssen C, Kantelhardt EJ, Vetter M
Diagnostics (Basel), 12(10):2527, 18 Oct 2022
Cited by: 3 articles | PMID: 36292215 | PMCID: PMC9601161
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
PIK3CA mutations in breast cancer
Reinhardt K, Stückrath K, Kaufhold S, Uleer C, Hanf V, Lantzsch T, Peschel S, John J, Pöhler M, Bauer M, Bürrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M
Research Square, 01 Apr 2022
Cited by: 0 articles | PPR: PPR476487
Add to export list Preprint v1
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
Hartung C, Porsch M, Stückrath K, Kaufhold S, Staege MS, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Pöhler M, Weigert E, Buchmann J, Bürrig KF, Schüler K, Bethmann D, Große I, Kantelhardt EJ, Thomssen C, Vetter M
Breast Care (Basel), 16(6):637-647, 19 Oct 2021
Cited by: 7 articles | PMID: 35082572 | PMCID: PMC8740062
Add to export list Free full text in Europe PMC
Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients.
Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Wickenhauser C, Thomssen C, Bartel F, Vetter M
Oncotarget, 10(20):1975-1992, 08 Mar 2019
Cited by: 6 articles | PMID: 30956778 | PMCID: PMC6443004
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, [...] KATHERINE Investigators
N Engl J Med, 380(7):617-628, 05 Dec 2018
Cited by: 932 articles | PMID: 30516102
Add to export list
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, [...] SOLE Investigators
Lancet Oncol, 19(1):127-138, 17 Nov 2017
Cited by: 41 articles | PMID: 29158011
Add to export list
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ
Breast Cancer Res, 19(1):112, 11 Oct 2017
Cited by: 57 articles | PMID: 29020998 | PMCID: PMC5637318
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X, SafeHer Study Group
Eur J Cancer, 82:237-246, 16 Jun 2017
Cited by: 21 articles | PMID: 28625777
Add to export list
Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy.
Berndt U, Leplow B, Schoenfeld R, Lantzsch T, Grosse R, Thomssen C
Breast Care (Basel), 11(4):240-246, 28 Jun 2016
Cited by: 8 articles | PMID: 27721710 | PMCID: PMC5040878
Add to export list Free full text in Europe PMC
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, [...] Schlag R
Ann Oncol, 25(12):2363-2372, 15 Sep 2014
Cited by: 75 articles | PMID: 25223482
Add to export list
Efficacy and patient satisfaction of breast conserving therapy for central breast cancer by the B technique.
Eggemann H, Ignatov A, Elling D, Lampe D, Lantzsch T, Weise M, Costa SD
Ann Surg Oncol, 20(11):3438-3445, 25 May 2013
Cited by: 7 articles | PMID: 23709056
Add to export list
Correction of Poland's Syndrome: Case Report and Review of the Current Literature.
Lantzsch T, Lampe D, Kantelhardt EJ
Breast Care (Basel), 8(2):139-142, 01 May 2013
Cited by: 5 articles | PMID: 24419214 | PMCID: PMC3683949
Add to export list Free full text in Europe PMC
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, [...] Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Lancet Oncol, 13(2):135-144, 17 Jan 2012
Cited by: 261 articles | PMID: 22257523
Add to export list
Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists.
Stang A, Trocchi P, Ruschke K, Schmidt-Pokrzywniak A, Holzhausen HJ, Löning T, Buchmann J, Thomssen C, Lantzsch T, Hauptmann S, Böcker W, Kluttig A
Histopathology, 59(5):939-949, 01 Nov 2011
Cited by: 7 articles | PMID: 22092405
Add to export list
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V
Breast Cancer Res Treat, 123(2):437-445, 10 Jul 2010
Cited by: 30 articles | PMID: 20623180
Add to export list
Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS).
Kluttig A, Trocchi P, Heinig A, Holzhausen HJ, Taege C, Hauptmann S, Boecker W, Decker T, Loening T, Schmidt-Pokrzywniak A, Thomssen C, Lantzsch T, Buchmann J, Stang A
BMC Cancer, 7:100, 14 Jun 2007
Cited by: 10 articles | PMID: 17570833 | PMCID: PMC1913923
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer.
Hefler LA, Grimm C, Lantzsch T, Lampe D, Koelbl H, Lebrecht A, Heinze G, Tempfer C, Reinthaller A, Zeillinger R
Breast Cancer Res Treat, 98(2):151-155, 15 Mar 2006
Cited by: 22 articles | PMID: 16538535
Add to export list
Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
Köbel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C, Hauptmann S
Int J Gynecol Pathol, 25(2):121-130, 01 Apr 2006
Cited by: 42 articles | PMID: 16633060
Add to export list
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.
Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R
Clin Cancer Res, 11(16):5718-5721, 01 Aug 2005
Cited by: 70 articles | PMID: 16115908
Add to export list
Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast.
Lebrecht A, Grimm C, Euller G, Ludwig E, Ulbrich E, Lantzsch T, Hefler L, Koelbl H
Int J Biol Markers, 19(3):236-239, 01 Jul 2004
Cited by: 13 articles | PMID: 15503826
Add to export list
Monocyte chemoattractant protein-1 serum levels in patients with breast cancer.
Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, Koelbl H
Tumour Biol, 25(1-2):14-17, 01 Jan 2004
Cited by: 76 articles | PMID: 15192307
Add to export list
The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.
Lantzsch T, Hefler L, Krause U, Kehl A, Goepel C, Koelbl H, Dunst J, Lampe D
Anticancer Res, 22(3):1925-1928, 01 May 2002
Cited by: 12 articles | PMID: 12168895
Add to export list

1-25 of 30 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Prognostic and predictive impact of NOTCH1 in early breast cancer.

PIK3CA-mutations in breast cancer.

Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients.

PIK3CA mutations in breast cancer

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.

Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

Efficacy and patient satisfaction of breast conserving therapy for central breast cancer by the B technique.

Correction of Poland's Syndrome: Case Report and Review of the Current Literature.

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists.

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS).

Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer.

Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.

Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.

Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast.

Monocyte chemoattractant protein-1 serum levels in patients with breast cancer.

The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.

Partnerships & funding